REG - Ergomed plc - Ergomed issue of shares
RNS Number : 0825GErgomed plc01 November 2018PRESS RELEASE
FOR IMMEDIATE RELEASE
Ergomed issues 102,491 shares for acquisition and deferred consideration
London, UK - 1 November 2018: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces the issue of a total of 102,491 new ordinary shares of 1p each in the Company ("Shares"). Of this amount, 49,390 Shares are being allotted to Dr Michael Forstner as deferred consideration in connection with the acquisition of his epidemiology consulting business announced on 25 May 2018. The remaining 53,101 Shares are being allotted to the seller as part consideration for the acquisition of Pharmacovigilance Services Limited, a small UK-based pharmacovigilance provider with particular expertise in audit and quality management.
An application has been made for the admission to trading on AIM of the Shares ("Admission"). Admission is expected to take place at 8.00am on 7 November 2018. The Shares will rank pari passu in all respects with Ergomed's existing shares in issue. Following Admission, the Company's enlarged issued share capital will comprise 44,991,438 Ordinary Shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 44,991,438. This figure of 44,991,438 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Stephen Stamp (Chief Executive Officer)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Matthew Neal / Olivia Manser
ergomed@consilium-comms.com
MC-Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDMSCLLFSSLFLLIIT
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement